Pharmacokinetics of serotonergic drugs: focus on OCD

Expert Opinion on Drug Metabolism & Toxicology
Donatella MarazzitiL Dell'Osso

Abstract

Although the treatment of obsessive-compulsive disorder (OCD), a common, chronic, and disabling psychiatric condition, has significantly improved in the last decades, with the demonstration of the specific effectiveness of serotonin reuptake inhibitors (SRIs), a large proportion of patients still show high relapse rates. In addition, pharmacological treatments should be maintained for years, so that the clinicians should take into account the pharmacokinetic changes in the long-term, which may be responsible for dangerous side effects or interactions. Areas covered: The aim of this paper was to review the literature on the pharmacokinetics of SSRIs and clomipramine, and on their pharmacokinetic parameters in OCD patients. Expert opinion: Although the literature on the pharmacokinetics of both clomipramine and SSRIs is consistent, data on pharmacokinetic parameters in OCD patients are very few. Given the impact of OCD, its chronicity requiring long-term treatments, together with the need to increase the clinical response rate, more studies in this field are urgently required.

References

Dec 1, 1992·Therapeutic Drug Monitoring·M H de VriesJ van Harten
Mar 1, 1992·Clinical Pharmacology and Therapeutics·S H SindrupT C Tasker
Dec 1, 1991·International Clinical Psychopharmacology·S J Warrington
Apr 1, 1991·The Journal of Clinical Psychiatry·S Lee
Jun 1, 1991·Clinical Pharmacokinetics·A E Balant-GorgiaL P Balant
Jan 1, 1989·Acta Psychiatrica Scandinavica. Supplementum·C M KayeW H Greb
Apr 1, 1987·British Journal of Clinical Pharmacology·M EichelbaumC Rittner
Jun 1, 1983·Archives of General Psychiatry·T R InselM Linnoila
Jan 1, 1981·Acta Pharmacologica Et Toxicologica·P Kragh-SørensenW Parnas
Oct 1, 1995·Clinical Pharmacology and Therapeutics·O SpigsetR Dahlqvist
Jan 1, 1994·European Journal of Clinical Pharmacology·K K NielsenL F Gram
Sep 1, 1994·Clinical Pharmacokinetics·E PeruccaE Spina
Mar 1, 1996·International Clinical Psychopharmacology·P Baumann
Nov 1, 1996·The American Journal of Psychiatry·L M KoranS Thiemann
Jan 1, 1997·Clinical Pharmacokinetics·R A RonfeldB A Baris
Feb 12, 1998·British Journal of Clinical Pharmacology·J SchmiderR I Shader
Mar 21, 1998·The American Journal of Psychiatry·W L StraussS R Dager
Apr 29, 1998·Journal of the American Academy of Child and Adolescent Psychiatry·J AldermanH F Johnston
Oct 6, 1999·British Journal of Clinical Pharmacology·H G XieA J Wood
Feb 15, 2000·British Journal of Clinical Pharmacology·D S Ou-YangH H Zhou
Feb 16, 2000·Pharmacology & Therapeutics·C Hiemke, S Härtter
Jul 14, 2001·Clinical Pharmacology and Therapeutics·J H WangH H Zhou
Jan 17, 2002·European Journal of Clinical Pharmacology·O SpigsetR Dahlqvist
Jul 24, 2002·The International Journal of Neuropsychopharmacology·Stefano PallantiUNKNOWN International Treatment Refractory OCD Consortium
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Oct 22, 2002·Expert Opinion on Investigational Drugs·William J Burke
Feb 7, 2003·The New England Journal of Medicine·William E Evans, Howard L McLeod
Jan 17, 2004·European Journal of Clinical Pharmacology·Adrián LLerenaEva M Peñas-LLedó

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.